<DOC>
	<DOCNO>NCT01485978</DOCNO>
	<brief_summary>This phase III , multi-centre , randomise , placebo-controlled , patient investigator-blind study paediatric patient early stage Alport syndrome assess safety efficacy ACEi ramipril slow disease progression . Alport syndrome stage describe extent renal damage loss function define : - 0 Microhaematuria without microalbuminuria ( usually birth ) - I Microalbuminuria ( 30-300 mg albumin/gCrea ) - II Proteinuria &gt; 300 mg albumin/gCrea - III &gt; 25 % decline normal renal function ( creatinine clearance ) - IV End stage renal failure ( ESRF ) Eligible patient Alport stag 0 I randomly assign 2:1 ratio receive daily ramipril placebo . In addition , Alport stage II patient may treat open Label . Eligible patient , whose parents/legal guardian refuse randomisation eligibility confirm , patient treat ramipril prior study , may treat open-label ramipril per protocol . The total number patient exceed 120 , number randomise patient exceed 60 , number patient treat open label Day 1 study aim approximately 60 . Randomised patient whose disease progress next disease level 3 year treatment period unblinded , open label ramipril treatment initiate continue , respectively , depend prior treatment randomisation .</brief_summary>
	<brief_title>Efficacy Safety Study Delay Renal Failure Children With Alport Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Nephritis , Hereditary</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Definitive diagnosis Alport syndrome : Kidney biopsy ( patient affect relative/s ) , and/or mutation analysis ( hemizygous Xchromosomal homozygous autosomalrecessive ) assessment criterion clinical diagnosis ( haematuria , positive family history regard kidney disease , ocular change , labyrinthine hearing loss ) Alport syndrome level 0 , I II screen ( microhaematuria without microalbuminuria microalbuminuria [ 30300 mg albumin/gCrea ] ) proteinuria &gt; 300 mg albumin/gCrea GFR &gt; 80ml/min ) . Patients Alport stage II subject randomization treat opel label . Aged â‰¥24 month &lt; 18 year screen Assent patient inform consent parents/legal guardian Uncertain diagnosis variant Alport syndrome heterozygous carrier Alport syndrome level III , IV ( albuminuria &gt; 300 mg/g Crea , creatinine clearance &lt; 60 mL/min , end stage renal failure [ ESRF ] ) Known allergy intolerance ramipril related compound Known contraindication ACEitherapy Additional chronic renal , pulmonary cardiac disease Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Alport Syndrome</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>renal fibrosis</keyword>
	<keyword>nephroprotection</keyword>
	<keyword>pediatric study</keyword>
</DOC>